ArticleScientific reports2026
Integrated wet lab and in silico discovery and characterization of bacteriophages with antibiotic synergy against multidrug resistant Acinetobacter baumannii.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The global rise of multidrug-resistant (MDR) bacteria has rendered many conventional antibiotics ineffective, creating an urgent need for alternative therapeutic strategies. Among these, bacteriophage-based approaches offer targeted, self-amplifying antimicrobial activity with the potential to complement or restore antibiotic efficacy. We report the isolation, characterization and host-adaptation of phages from environmental samples using a set of standard experimental procedures. Using wastewater as the source, we isolated four Caudoviricetes phages infecting an MDR Acinetobacter baumannii clinical strain (Abau1). Genome sequencing and host‐prophage filtering identified two strictly lytic phages (ΦAb1-SL1 and ΦAb1-SL2) for characterization, whilst two phages were host-integrated. ΦAb1-SL1 demonstrated potent synergistic killing with cephalosporin antibiotics: checkerboard assays revealed strong synergy with cefiderocol, ceftazidime and cefotaxime, the first result confirmed by a time-killing assay. Conversely, no synergy was seen with carbapenems. Under our host‐adaptation protocol, ΦAb1-SL1 broadened its host-spectrum infecting a previously resistant A. baumannii strain (Abau2). The resulting adapted phage (ΦAb2-SL1) retained infectivity of both hosts, albeit at a lower titer on the new host. The observed phage–antibiotic synergy with cefiderocol underscores the therapeutic promise of combined phage–antibiotic regimens against MDR A. baumannii and highlights the efforts of a translational approach for assembling phage libraries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.